Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • SCORE2-HF
Predicting Heart Failure Before It Starts: The New SCORE2-HF Model and Clinical Consensus for Cardiovascular Risk Assessment
Posted inCardiology Internal Medicine news

Predicting Heart Failure Before It Starts: The New SCORE2-HF Model and Clinical Consensus for Cardiovascular Risk Assessment

Posted by MedXY By MedXY 03/11/2026
This article details the SCORE2-HF risk model, a newly validated tool designed to estimate 10-year and 30-year heart failure risks in asymptomatic individuals, enabling earlier intervention and personalized cardiovascular care across diverse European risk regions.
Read More
  • Sport-Related Head Exposure Characteristics and Health Outcomes in Former Collegiate Athletes: A CARE Consortium Study
  • High-Level EBNA-1 Antibodies: A Precise Biomarker for Differentiating Multiple Sclerosis From MOGAD and NMOSD
  • Long-Term Thyroid Toxicity Burden in Children Who Received Treatment for High-Risk Neuroblastoma
  • Distinctive Endocrine Profiles and Hyperphagia in Rare Genetic Neurodevelopmental Disorders: Beyond the Prader-Willi Paradigm
  • Tirzepatide Outperforms Dulaglutide in Cardiovascular Risk Reduction: Insights from Real-World Target-Trial Emulations
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in